Trial Profile
Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 21 Oct 2011 Actual patient no is 32 as reported by ClinicalTrials.gov.
- 21 Oct 2011 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
- 21 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.